Opinion|Videos|August 12, 2024
ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What future research is needed to further support decision-making when using CDK4/6 inhibitors for early breast cancer?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
2
TrumpRx Launch Brings Savings—and Uncertainty
3
Exploring Identity, Appearance Experiences Among Patients With Alopecia
4
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
5
